Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 471

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma

Open access
Zhu, Liya, Kalimuthu, Senthilkumar, Gangadaran, Prakash, Oh, Ji Min, Lee, Ho Won, Baek, Se Hwan, Jeong, Shin Young, Lee, Sang-Woo, Lee, Jaetae, Ahn, Byeong-Cheol·2017·Theranostics

Abstract

Objective: Exosomes are nanovesicles that are released from normal and tumor cells and are detectable in cell culture supernatant and human biological fluids.Although previous studies have explored exosomes released from cancer cells, little is understood regarding the functions of exosomes released by normal cells.Natural killer (NK) cells display rapid immunity to metastatic or hematological malignancies, and efforts have been undertaken to clinically exploit the antitumor properties of NK cells.However, the characteristics and functions of exosomes derived from NK cells remain unknown.In this study, we explored NK cell-derived exosome-mediated antitumor effects against aggressive melanoma in vitro and in vivo.Methods: B16F10 cells were transfected with enhanced firefly luciferase (effluc) and thy1.1 genes, and thy1.1-positive cells were immunoselected using microbeads.The resulting B16F10/effluc cells were characterized using reverse transcriptase polymerase chain reaction (RT-PCR), western blotting, and luciferase activity assays.Exosomes derived from NK-92MI cells (NK-92 Exo) were isolated by ultracentrifugation and density gradient ultracentrifugation.NK-92 Exo were characterized by transmission electron microscopy and western blotting.We also performed an enzyme-linked immunosorbent assay to measure cytokines retained in NK-92 Exo cells.The in vitro cytotoxicity of NK-92 Exo against the cancer cells was determined using a bioluminescence imaging system (BLI) and CCK-8 assays.To investigate the possible side effects of NK-92 Exo on healthy cells, we also performed the BLI and CCK-8 assays using the human kidney Phoenix™-Ampho cell line.Flow cytometry and western blotting confirmed that NK-92 Exo induced apoptosis in the B16F10/effluc cells.In vivo, we used a B16F10/effluc cell xenograft model to detect the immunotherapeutic effect of NK-92 Exo.We injected NK-92 Exo into tumors, and tumor growth progression was monitored using the IVIS Lumina imaging system and ultrasound imaging.Tumor mass was monitored after in vivo experiments.Results: RT-PCR and western blotting confirmed effluc gene expression and protein levels in B16F10/effluc cells.B16F10/effluc activity was found to increase with increasing cell numbers, using BLI assay.For NK-92 Exo characterization, western blotting was performed on both ultracentrifuged and density gradient-isolated exosomes.The results confirmed that NK cell-derived exosomes express two typical exosome proteins, namely CD63 and ALIX.We demonstrated by western blot analysis that NK-92 Exo presented two functional NK proteins, namely perforin and FasL.Moreover, we confirmed the membrane expression of FasL.The enzyme-linked immunosorbent assay results indicated that NK-92 Exo can secrete tumor necrosis factor (TNF)-α, which affected the cell proliferation signaling pathway.The antitumor effect of NK-92 Exo against B16F10/effluc cells in vitro was confirmed by BLI (p < 0.001) and CCK-8 assays (p < 0.001).Furthermore, in normal healthy cells, even after 24 h of co-culture, NK-92 Exo did not exhibit significant side effects.In the in vivo experiments, tumors in the vehicle control group were significantly increased, compared with those in the NK-92 Exo-treated group (p < 0.05). Conclusion:The results of the current study suggest that exosomes derived from NK cells exert cytotoxic effects on melanoma cells and thus warrant further development as a potential immunotherapeutic strategy for cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/thno.18752

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 471

Metadata

Authors
Zhu, L., Kalimuthu, S., Gangadaran, P., Oh, J. M., Lee, H. W., Baek, S. H., Jeong, S. Y., Lee, S.-W., Lee, J., & Ahn, B.-C.
Venue
Theranostics
Published
2017
Volume
7
Issue
10
Pages
2732-2745
ISSN
1838-7640 (ISSN-L)
OpenAlex
W2734802465
Cited by
471
References
50
FWCI
11.16
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.